E 7046

Drug Profile

E 7046

Alternative Names: E7046

Latest Information Update: 13 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Inc
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Prostaglandin E EP4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rectal cancer; Solid tumours

Most Recent Events

  • 08 Sep 2017 Interim adverse events, pharmacokinetics data from phase I trial in rectal cancer presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 17 May 2017 Phase-I clinical trials in Rectal cancer (Neoadjuvant therapy, First-line therapy) in France, United Kingdom (PO) (NCT03152370)
  • 03 Aug 2015 Phase-I clinical trials in Solid tumours in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top